News
-
The FDA said in a Drug Safety Communication that it has approved the removal of Boxed Warnings about asthma-related deaths from ICS/LABA combination inhalers. The inhalers affected by the change are Advair Diskus, Advair HFA,… Read more . . .
-
According to Korea Biomedical Review, Korean pharmaceutical company Huons has licensed Zephirus busesonide/salmeterol, a dry powder formulation delivered using the Axahaler capsule-based inhaler, from Belgian pharmaceutical company Laboratoires SMB. Korea Biomedical Review reported that Huons… Read more . . .
-
Iconovo AB announced that it has signed an agreement with Intas Pharmaceuticals for development and licensing of a DPI for the treatment of asthma and COPD, including the dry powder formulation and a device based… Read more . . .
-
Neurodyn Cognition (NCI), a Canadian company developing an intranasal therapy for Alzheimer’s disease, has named Anthony Giovinazzo as a director and Executive Chairman. Giovinazzo was most recently President and CEO of Cynapsus Therapeutics, which was… Read more . . .
-
DDL 2017 drew 750 delegates, a record number, to the Edinburgh International Conference Centre. Topics that received sustained attention over the course of the 3-day meeting included the use of modeling techniques, development of inhaled… Read more . . .
-
Medical Developments International (MVP) has announced that the Decentralized Procedure for its Penthrox methoxyflurane inhaler marketing application has been completed, and the inhaler has been approved in an additional 22 countries. Penthrox has been available… Read more . . .
-
Glenmark Pharmaceuticals has announced that a 52-week Phase 3 trial of its Ryaltris mometasone furoate/olopatadine hydrochloride nasal spray for the treatment of perennial allergic rhinitis (PAR) met its primary and secondary endpoints. The company said… Read more . . .
-
Cambustion presented its Aerodynamic Aerosol Classifier (AAC), a monodisperse aerosol generation system, to a pharmaceutical audience for the first time at DDL 2017, the company said. According to the company, the AAC, which does not… Read more . . .
-
Insys Therapeutics has announced the initiation of a Phase 1 proof-of-concept study to determine whether an epinephrine nasal spray for the treatment of anaphylaxis is bioequivalent to intramuscular injection of epinephrine. The trial will compare… Read more . . .
-
Mucodel Pharma has announced that a PK study of its intranasal naloxone met its endpoints and showed that the formulation based on its Co-Gel technology delivered the dose of naloxone faster than both an intranasal… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK